Physician profile
Mark V Silver
NPI 1750354437
$47,482.54
in general payments reported to CMS, 2019-2025
15 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $14K · 2021: $2,013 · 2022: $3,622 · 2023: $1,323 · 2024: $1,173 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,841.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $36,120.33 | 2019-2022 | |
| Abbott Laboratories | $7,073.15 | 2019-2025 | Proclaim, Octrode, Penta |
| Medtronic, INC. | $1,203.07 | 2021-2023 | Intellis Adaptivestim |
| Captiva Spine INC | $992.21 | 2022 | |
| Alphatec Spine, INC | $682.00 | 2019 | |
| Nevro Corp. | $370.77 | 2021-2022 | |
| Boston Scientific Corporation | $288.34 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Penumbra, INC. | $198.96 | 2019 | |
| Carlsmed, INC. | $181.98 | 2022 | |
| Shockwave Medical, INC | $160.17 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Orthofix Medical, INC. | $103.21 | 2022 | |
| Relievant Medsystems, INC. | $37.68 | 2023 | Intracept |
| Medtronic USA, INC. | $31.42 | 2019-2020 | |
| Bioventus LLC | $29.99 | 2023 | Stimrouter Implantable Kit |
| Surgalign Spine Technologies, INC. | $9.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.